

REMARKS

Claims 1, 9-21, 29-31, 55 and 56 are now pending. Claims 1, 13, 18, 55 and 56 have been amended to recite the appropriate sequence identifiers. These claim amendments have been made without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents. No new matter is added by these amendments.

The February 21, 2003 Office Communication forwarding a Notice to Comply stated that the application fails to comply with the requirements of 37 CFR 1.821 to 1.825, and specifically stated that the drawings contain sequences without the requisite identifiers. It is respectfully submitted that the amendments to the specification, drawings and claims submitted herewith place the application in compliance.

Figure 9 as filed depicted amino acid sequences of cpn60 family members without reference to SEQ ID NOs in either the figure itself or in the brief description of the figure. By the amendments to figure 9 and the brief description of figure 9 submitted herewith, the SEQ ID NOs that correspond to each of the sequences shown in figure 9 have been identified. Amended figure 9 and the amended brief description of figure 9 now contains reference to SEQ ID NOs 12, 13 and 15. SEQ ID Nos 12 and 13 were present in the Sequence Listing filed on April 19, 2000. Although the amino acid sequence corresponding to SEQ ID NO 15 was present in the specification as filed, it was omitted from the Sequence Listing filed on April 19, 2000. The Sequence Listing submitted herewith incorporates SEQ ID NO 15 thereby correcting this omission.

In addition, although the amino acid sequences corresponding to SEQ ID NOs 16, 17 and 18 were present in the specification as filed, these sequences were omitted from the Sequence Listing filed on April 19, 2000. The Sequence Listing submitted herewith incorporates SEQ ID NOs 16, 17 and 18, thereby correcting this omission.

Applicants respectfully request acceptance of the enclosed paper copy and computer readable (floppy disk) form of the corrected Sequence Listing.

It is respectfully submitted that the corrected Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R. §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.

It is respectfully asserted that the sequence disclosure contained in the application now fully complies with the requirements set forth in 37 C.F.R. § 1.821 to § 1.825. Accordingly, reconsideration and withdrawal of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply") is respectfully requested.

CONCLUSION

Reconsideration and withdrawal reconsideration and withdrawal of the Office Communication and Notice to Comply is respectfully requested in view of the remarks herein.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for the Applicant

By: Thomas J. Kowalski by Angela M.
Thomas J. Kowalski
Reg. No. 32,147
Angela M. Nigro-Collison
Reg. No. 51,107
(212) 588-0800

Nigro-Collison